Evidence map›Paper›PMID 28204173›Full record

ArticleEndocrinology2017

ANGPTL8 Blockade With a Monoclonal Antibody Promotes Triglyceride Clearance, Energy Expenditure, and Weight Loss in Mice.

Viktoria Gusarova, Serena Banfi, Corey A Alexa-Braun, Lisa M Shihanian, Ivory J Mintah, Joseph S Lee, Yurong Xin, Qi Su, Vishal Kamat, Jonathan C Cohen and 5 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Endocrinology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.

0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed
5.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

48 citing papers in PubMed, 80 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. A unified model for regulating lipoprotein lipase activity.Trends in endocrinology and metabolism: TEM · 2024
    Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 1 country.

Viktoria GusarovaRegeneron Pharmaceuticals, Inc., Tarrytown, New York, 10591.
Serena BanfiDepartment of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas 75390.
Corey A Alexa-BraunRegeneron Pharmaceuticals, Inc., Tarrytown, New York, 10591.
Lisa M ShihanianRegeneron Pharmaceuticals, Inc., Tarrytown, New York, 10591.
Ivory J MintahRegeneron Pharmaceuticals, Inc., Tarrytown, New York, 10591.
Joseph S LeeRegeneron Pharmaceuticals, Inc., Tarrytown, New York, 10591.
Yurong XinRegeneron Pharmaceuticals, Inc., Tarrytown, New York, 10591.
Qi SuRegeneron Pharmaceuticals, Inc., Tarrytown, New York, 10591.
Vishal KamatRegeneron Pharmaceuticals, Inc., Tarrytown, New York, 10591.
Jonathan C CohenDepartment of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas 75390.
Helen H HobbsDepartment of Molecular Genetics, University of Texas Southwestern Medical Center, Dallas, Texas 75390.
Brian ZambrowiczRegeneron Pharmaceuticals, Inc., Tarrytown, New York, 10591.
George D YancopoulosRegeneron Pharmaceuticals, Inc., Tarrytown, New York, 10591.
Andrew J MurphyRegeneron Pharmaceuticals, Inc., Tarrytown, New York, 10591.
Jesper GromadaRegeneron Pharmaceuticals, Inc., Tarrytown, New York, 10591.
Regeneron (United States) · USThe University of Texas Southwestern Medical Center · US

Funding

TRANSCRIPTIONAL REGULATION OF LDL RECEPTOR PROMOTERP01HL020948 · NHLBI · UT SOUTHWESTERN MEDICAL CENTER · PI GOLDSTEIN, JOSEPH L · 1985 to 2021
$103.1M
NHLBI NIH HHS P01 HL020948
6 · The paper itself

Abstract

Angiopoietin-like protein (ANGPTL)8 is a negative regulator of lipoprotein lipase-mediated plasma triglyceride (TG) clearance. In this study, we describe a fully human monoclonal antibody (REGN3776) that binds monkey and human ANGPTL8 with high affinity. Inhibition of ANGPTL8 with REGN3776 in humanized ANGPTL8 mice decreased plasma TGs and increased lipoprotein lipase activity. Additionally, REGN3776 reduced body weight and fat content. The reduction in body weight was secondary to increased energy expenditure. Finally, single administration of REGN3776 normalized plasma TGs in dyslipidemic cynomolgus monkeys. In conclusion, we show that blockade of ANGPTL8 with monoclonal antibody strongly reduced plasma TGs in mice and monkeys. These data suggest that inhibition of ANGPTL8 may provide a new therapeutic avenue for the treatment of dyslipidemia with beneficial effects on body weight.

Indexed as

Energy MetabolismWeight LossAngiopoietin-Like Protein 8Angiopoietin-like ProteinsAngiopoietinsAnimalsAntibodies, MonoclonalDyslipidemiasHumansKineticsLipoprotein LipaseMacaca fascicularisMiceMice, TransgenicTriglyceridesAngiopoietin-Like Protein 8Angiopoietin-like ProteinsAngiopoietinsANGPTL8 protein, mouseAntibodies, MonoclonalLipoprotein LipaseTriglycerides

Identifiers

PMID28204173
PMCPMC5460832
OpenAlexW2589215191

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.